DEA Rescheduling Process: How Federal Cannabis Classification Works

Executive Summary

The DEA rescheduling process represents the most significant potential shift in federal cannabis policy since the Controlled Substances Act was enacted in 1970. On May 21, 2024, the Department of Justice published a notice of proposed rulemaking to transfer marijuana from Schedule I to Schedule III of the Controlled Substances Act—a move that would acknowledge cannabis has accepted medical use and lower abuse potential than substances like heroin or LSD. The process has been marked by procedural complexity, political controversy, and unprecedented public engagement, with the DEA receiving over 43,000 public comments during the initial comment period. As of April 28, 2026, the DEA withdrew its initial hearing notice and initiated new hearing proceedings under Executive Order 14370, extending a process that has already spanned multiple presidential administrations. While rescheduling would not legalize cannabis federally or resolve the conflict between state and federal law, it would eliminate the punitive 280E tax provision affecting state-legal cannabis businesses, potentially saving the industry billions annually, and could facilitate expanded medical research. The outcome will affect hundreds of thousands of jobs, tens of billions in annual commerce, millions of medical patients, and the criminal justice system's approach to cannabis enforcement.

Why This Matters

The DEA's rescheduling decision will determine the fate of a $30+ billion legal cannabis industry, affect millions of medical patients, and reshape criminal justice policy nationwide. The stakes extend far beyond the cannabis industry itself. Over 40 states have legalized cannabis in some form, creating a massive state-federal legal conflict that affects banking, taxation, research, employment, and criminal enforcement.

For the cannabis industry, rescheduling to Schedule III would eliminate Internal Revenue Code Section 280E, which currently prohibits state-legal cannabis businesses from deducting ordinary business expenses on federal tax returns. Industry analysts estimate this change alone could save multi-state operators between $1.5 billion and $3 billion annually in tax liability, fundamentally altering profitability calculations and potentially triggering consolidation and expansion. Publicly traded cannabis companies have seen stock valuations swing by billions based on rescheduling speculation.

For medical patients, Schedule III status would acknowledge federal recognition of cannabis's medical utility for the first time, potentially expanding access through the Veterans Administration, facilitating insurance coverage discussions, and reducing stigma. Approximately 5-7 million Americans currently use state-legal medical cannabis for conditions ranging from chronic pain to epilepsy to PTSD. Research institutions would gain substantially easier pathways to study cannabis, potentially accelerating clinical trials and FDA approval processes for cannabis-derived medications.

The criminal justice implications remain complex. While rescheduling would not decriminalize cannabis possession or eliminate federal prohibition, it would reduce maximum penalties and could influence prosecutorial discretion. Approximately 350,000 Americans were arrested for cannabis-related offenses in 2023, the vast majority for simple possession. Advocacy groups argue that rescheduling without broader reform fails to address mass incarceration and disproportionate enforcement against communities of color.

Financial institutions currently operating under guidance rather than clear legal authority would gain regulatory clarity, potentially opening traditional banking services to an industry that has operated largely on cash. Interstate commerce questions would intensify, as Schedule III substances can move across state lines under proper licensing—a provision that could fundamentally restructure the state-by-state siloed market structure.

Background and History

The path to potential rescheduling began with the Controlled Substances Act of 1970 and has accelerated dramatically since 2022 through a complex interplay of scientific review, political pressure, and administrative procedure.

The Controlled Substances Act Framework (1970)

President Richard Nixon signed the Controlled Substances Act into law on October 27, 1970, establishing five schedules of controlled substances based on medical use, abuse potential, and safety. Cannabis was placed in Schedule I, the most restrictive category, defined as substances with "no currently accepted medical use" and "high potential for abuse." This classification put cannabis in the same category as heroin, LSD, and peyote, while cocaine and methamphetamine were placed in Schedule II, acknowledging their medical applications despite abuse potential.

The CSA established procedures for rescheduling substances under 21 U.S.C. § 811, requiring the Attorney General (who delegated authority to the DEA) to request a scientific and medical evaluation from the Department of Health and Human Services. The statute specifies eight factors for evaluation, including the substance's actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope and significance of abuse, and risk to public health.

Early Rescheduling Petitions (1972-2016)

The National Organization for the Reform of Marijuana Laws filed the first rescheduling petition in 1972, initiating a 22-year administrative and legal battle. DEA Administrative Law Judge Francis Young ruled in 1988 that cannabis should be rescheduled to Schedule II, famously stating that cannabis is "one of the safest therapeutically active substances known to man." DEA Administrator John Lawn rejected this recommendation in 1989, a decision upheld by the D.C. Circuit Court of Appeals in 1994.

Subsequent petitions in 1995, 2002, and 2011 followed similar patterns: years of administrative delay, HHS scientific review concluding cannabis met Schedule I criteria, and DEA denial. The 2011 petition, filed by governors of Washington and Rhode Island, was denied in 2016 after a five-year review. The DEA's 2016 denial letter acknowledged growing state legalization but maintained that cannabis lacked "adequate and well-controlled studies proving efficacy" required for accepted medical use under the agency's five-part test.

The Biden Administration Initiative (2022-2024)

On October 6, 2022, President Joe Biden issued a presidential memorandum directing HHS Secretary Xavier Becerra and Attorney General Merrick Garland to "review expeditiously how marijuana is scheduled under federal law." This marked the first time a sitting president had directly initiated a rescheduling review rather than responding to external petitions. The directive came alongside presidential pardons for federal simple possession convictions and reflected shifting political calculations as public support for legalization exceeded 70 percent in most polling.

HHS completed its scientific review in August 2023, recommending rescheduling to Schedule III. The recommendation, based on an eight-factor analysis conducted by the Food and Drug Administration, concluded that cannabis has lower abuse potential than Schedule I or II substances and has currently accepted medical use in treatment in the United States. The FDA analysis noted that 38 states had legalized medical cannabis, that healthcare providers were recommending cannabis under state law, and that cannabis showed lower physical dependence liability than other controlled substances.

The DEA received HHS's recommendation in late August 2023 and initiated its own independent review. Under the CSA, HHS's scientific and medical findings are binding on scheduling factors related to medical use and abuse potential, but the DEA retains final decision-making authority and must consider additional factors including international treaty obligations and enforcement considerations.

The Notice of Proposed Rulemaking (May 2024)

On May 21, 2024, the DEA published its notice of proposed rulemaking in the Federal Register, proposing to reschedule cannabis from Schedule I to Schedule III. The 92-page document detailed the agency's analysis of the eight statutory factors, substantially adopting HHS's scientific conclusions while addressing enforcement and international treaty questions. The NPRM acknowledged that rescheduling would not resolve the state-federal conflict, would not legalize cannabis for recreational use, and would not permit cannabis businesses to operate without DEA registration as manufacturers or distributors of controlled substances.

The proposal triggered an unprecedented public response. During the initial 60-day comment period, the DEA received over 43,000 submissions—far exceeding typical rulemaking engagement. Comments ranged from major medical organizations supporting rescheduling based on emerging evidence, to law enforcement groups warning of increased youth access, to cannabis industry stakeholders seeking full descheduling rather than Schedule III placement, to criminal justice reform advocates arguing rescheduling without expungement provisions perpetuates injustice.

Hearing Proceedings and Withdrawal (2024-2026)

On August 29, 2024, the DEA published a notice of hearing, granting requests from multiple parties to present oral testimony and cross-examine witnesses on the rescheduling proposal. The formal hearing process, governed by 21 CFR Part 1316, resembles a trial with discovery, pre-hearing statements, witness lists, and an administrative law judge presiding. Parties granted participant status included medical cannabis advocacy organizations, pharmaceutical industry representatives, law enforcement associations, and individual researchers.

The hearing process became entangled in political transitions and executive branch policy shifts. On April 28, 2026, the DEA published a withdrawal notice, terminating the pending hearing proceedings and announcing new hearing proceedings would be initiated. The withdrawal cited Executive Order 14370 and stated that terminating existing proceedings and starting fresh represented "the most expeditious manner of completing the rulemaking process in accordance with Federal law." The unusual procedural move extended timeline uncertainty and raised questions about whether the new administration sought to alter the rescheduling outcome or merely restructure the administrative process.

Key Players

Drug Enforcement Administration

The DEA holds final decision-making authority on rescheduling under delegated authority from the Attorney General. As the lead federal drug enforcement agency, the DEA has historically defended cannabis's Schedule I status through six decades and multiple rescheduling petitions. The agency's institutional culture emphasizes enforcement and international drug control treaty obligations. DEA Administrator Anne Milgram oversaw the initial review process and NPRM publication, while leadership transitions in 2025-2026 coincided with the hearing withdrawal and restart. The DEA's internal debate balances scientific evidence from HHS against law enforcement concerns, international treaty compliance, and the practical reality that rescheduling a widely used substance creates complex regulatory challenges for an agency built around prohibition.

Department of Health and Human Services / FDA

HHS provides the binding scientific and medical evaluation that forms the foundation of any rescheduling decision. The Food and Drug Administration, operating within HHS, conducted the comprehensive eight-factor analysis that concluded cannabis meets Schedule III criteria. FDA scientists reviewed epidemiological data on use patterns, pharmacological studies on dependence liability, state medical program data, and international scheduling approaches. The agency's 2023 recommendation represented a significant departure from previous HHS positions and reflected accumulating clinical evidence, state program experience, and evolving understanding of cannabis pharmacology. HHS Secretary Xavier Becerra championed the review, while FDA Commissioner Robert Califf emphasized the agency's commitment to following scientific evidence despite political pressures.

White House and Executive Branch

Presidential directives initiated the current rescheduling process and executive orders have shaped its procedural path. President Biden's October 2022 memorandum launched the review, reflecting campaign commitments and shifting Democratic Party consensus toward cannabis reform. The administration framed rescheduling as a criminal justice and scientific integrity issue, though stopped short of endorsing full legalization. The transition to a new administration in 2025 introduced uncertainty, with Executive Order 14370 triggering the hearing process restart. White House domestic policy staff coordinate across agencies, balancing public health perspectives, criminal justice reform advocates, and political calculations around a policy that polls strongly with voters under 50 but faces skepticism from traditional law enforcement constituencies.

Cannabis Industry and Trade Associations

Multi-state operators, ancillary businesses, and industry trade groups have billions in market capitalization riding on the rescheduling outcome. The National Cannabis Industry Association, the U.S. Cannabis Council, and state-level trade groups submitted detailed comments emphasizing 280E tax relief and banking access. Publicly traded MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have seen stock prices fluctuate 30-50 percent based on rescheduling news. Industry positions are not monolithic—some advocate for Schedule III as a pragmatic step forward, while others argue it perpetuates federal prohibition and prefer full descheduling. Smaller operators and social equity licensees have raised concerns that 280E relief will disproportionately benefit large MSOs with resources to survive current tax burdens, potentially accelerating market consolidation.

Medical and Scientific Organizations

Professional medical societies have evolved from skepticism to cautious support for rescheduling based on accumulating evidence. The American Medical Association, which originally supported cannabis prohibition in the 1930s, now supports rescheduling to facilitate research. The American Academy of Pediatrics maintains concerns about youth use but acknowledges medical applications. Organizations representing specialists treating conditions where cannabis shows promise—including the American Academy of Neurology for epilepsy and the American Pain Society for chronic pain—have submitted supportive comments. Research institutions including the University of Mississippi, which holds the federal cannabis cultivation monopoly, and major academic medical centers seek expanded research access that Schedule III would facilitate.

Law Enforcement and Opposition Groups

Police associations, prosecutors, and anti-legalization advocacy groups argue rescheduling sends the wrong message and threatens public safety. Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, leads organized opposition, arguing that cannabis potency has increased dramatically since the 1970s and that rescheduling ignores mental health and addiction risks. The National Sheriffs' Association and Major County Sheriffs of America have expressed concerns about impaired driving enforcement and youth access. These groups emphasize that Schedule III substances are still prohibited for recreational use and that rescheduling creates regulatory complexity without resolving enforcement challenges. Some opposition comes from unexpected quarters—certain pharmaceutical industry segments concerned about cannabis competition with prescription medications.

Criminal Justice Reform and Social Equity Advocates

Organizations focused on mass incarceration and racial justice argue that rescheduling without expungement and reinvestment fails to address prohibition's harms. The Drug Policy Alliance, the Last Prisoner Project, and the Marijuana Policy Project have submitted comments supporting rescheduling as a step forward while emphasizing it leaves federal prohibition intact. These groups note that Black Americans are arrested for cannabis offenses at nearly four times the rate of white Americans despite similar usage rates, and that rescheduling does nothing for the estimated 40,000 people currently incarcerated for federal cannabis offenses. They advocate for comprehensive reform including expungement, resentencing, and community reinvestment rather than industry-focused tax relief.

Legal and Regulatory Framework

The rescheduling process operates within a complex statutory framework established by the Controlled Substances Act, constrained by international treaties, and complicated by federalism questions.

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes the fundamental legal architecture. Section 811 specifies the rescheduling process and the eight factors that must be considered: the substance's actual or relative potential for abuse; scientific evidence of its pharmacological effect; the state of current scientific knowledge; its history and current pattern of abuse; the scope, duration, and significance of abuse; what risk there is to public health; its psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance already scheduled.

The statute creates a unique division of authority between HHS and DEA. Under 21 U.S.C. § 811(b), the Attorney General (through DEA) must request a scientific and medical evaluation from HHS, and HHS's findings on scientific and medical matters are binding. However, the DEA makes the final scheduling decision considering additional factors including international treaty obligations and enforcement practicality. This division has created tension in the current process, with HHS's Schedule III recommendation binding on medical use and abuse potential questions but leaving DEA discretion on implementation.

The Administrative Procedure Act, 5 U.S.C. § 551 et seq., governs the rulemaking process itself. The DEA must provide notice, accept public comments, and respond to significant issues raised. The formal hearing process, triggered when parties request it, follows procedures in 21 CFR Part 1316, which incorporate elements of the APA's formal rulemaking requirements. These procedures, while ensuring due process, extend timelines significantly—the hearing on MDMA rescheduling in the 1980s took over three years from notice to final decision.

International treaty obligations add another layer of complexity. The United States is party to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. Cannabis is listed in Schedule I and Schedule IV of the 1961 Convention. In December 2020, the UN Commission on Narcotic Drugs voted to remove cannabis from Schedule IV (the most restrictive category) but retained it in Schedule I. U.S. rescheduling to Schedule III domestically would not violate treaty obligations, as the treaties require prohibition but allow countries to determine severity of controls and penalties. However, DEA has historically cited treaty obligations as a factor weighing against rescheduling.

The Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. This provision has been the primary financial burden on state-legal cannabis businesses, forcing them to pay effective tax rates of 70 percent or higher. Rescheduling to Schedule III would eliminate 280E applicability, as the statute explicitly applies only to Schedule I and II substances. This change requires no additional Congressional action—it would occur automatically upon rescheduling.

The conflict between state and federal law raises fundamental federalism questions. Under the Supremacy Clause of the Constitution, federal law preempts conflicting state law. However, the anti-commandeering doctrine prevents the federal government from requiring states to enforce federal law. States can legalize cannabis under state law, but cannot immunize conduct from federal prosecution. Rescheduling to Schedule III would not resolve this conflict—cannabis would remain federally prohibited for recreational use, and state-legal businesses would still technically violate federal law, though they could potentially register with DEA as handlers of Schedule III substances.

The Gun Control Act of 1968, as interpreted by ATF, prohibits cannabis users from possessing firearms, even in states where cannabis is legal. This prohibition is based on cannabis's status as a controlled substance, not its specific schedule, so rescheduling would not resolve the conflict. However, the Fifth Circuit's decision in United States v. Daniels (2023) and subsequent cases have raised constitutional questions about this prohibition that may ultimately require Supreme Court resolution.

State-by-State Landscape

Federal rescheduling will interact differently with the patchwork of state cannabis laws, affecting 40+ state programs in varying ways.

State Category	Number of States	Rescheduling Impact
Adult-use legal	24 states + DC	Major 280E tax relief for businesses; no change to state-federal conflict on recreational use
Medical only	14 states	Federal acknowledgment of medical use; potential VA and research expansion
CBD/low-THC only	7 states	Possible catalyst for medical program expansion
Fully prohibited	5 states	Reduced federal penalties may influence state policy debates

California

As the largest legal cannabis market with over $5 billion in annual sales, California operators would see the most significant aggregate 280E relief. The state's high tax burden—combining state excise tax, local taxes, and effective federal rates over 70 percent—has driven consumers to the illicit market. Rescheduling could improve licensed market competitiveness, though California's regulatory complexity and local control issues would remain. Major MSOs including Glass House Brands and Harborside have headquarters in California and would benefit substantially from improved margins.

Florida

Florida's medical-only program serves over 800,000 registered patients, one of the nation's largest medical populations. Rescheduling would federally acknowledge medical use, potentially influencing the state's ongoing adult-use legalization debate. Trulieve, the nation's largest cannabis company by revenue, is headquartered in Florida and operates the most dispensaries statewide. The state's November 2024 adult-use ballot initiative failed to reach the 60 percent threshold, but rescheduling could shift political dynamics for future attempts.

New York

New York's adult-use program, launched in 2022, has struggled with slow licensing and illicit market competition. The state's social equity focus—prioritizing licenses for individuals harmed by prohibition—could see improved viability as 280E relief makes equity licensees more financially sustainable. However, rescheduling does nothing to address the state's regulatory bottlenecks or the estimated 1,500+ unlicensed storefronts operating in New York City.

Texas

Texas maintains one of the nation's most restrictive medical programs, limited to low-THC cannabis for a narrow list of conditions. Federal rescheduling acknowledging medical use could influence the Republican-controlled legislature's calculus, particularly as polling shows majority support among Texas voters for medical expansion. However, the state's conservative political culture and law enforcement opposition make rapid change unlikely regardless of federal scheduling.

Idaho, Nebraska, and Kansas

These states maintain complete prohibition with no medical exceptions. Federal rescheduling to Schedule III would reduce maximum federal penalties for possession and cultivation, potentially creating pressure on state lawmakers as neighboring states operate legal markets. However, state law enforcement would retain full authority to prosecute under state statutes, and political opposition remains strong in these conservative states.

Market and Business Implications

Rescheduling to Schedule III would trigger the most significant financial restructuring in cannabis industry history, with implications cascading through cultivation, retail, investment, and ancillary services.

The elimination of 280E represents an immediate margin expansion of 30-50 percent for most operators. Multi-state operators currently paying effective tax rates of 70-80 percent would drop to normal corporate rates around 21-25 percent. For a mid-sized MSO with $200 million in revenue and $40 million in EBITDA, 280E relief could translate to $25-35 million in annual tax savings. These savings would flow directly to bottom lines, fund expansion, or enable price reductions to compete with illicit markets.

Public market valuations would likely see immediate appreciation. The combined market capitalization of the top 20 publicly traded U.S. cannabis companies exceeds $15 billion, with stocks trading at significant discounts to revenue compared to other consumer packaged goods or pharmaceutical companies. Analysts project that rescheduling could trigger 50-100 percent stock appreciation as institutional investors currently restricted by federal illegality enter the sector. However, Schedule III status still leaves cannabis federally prohibited for recreational use, potentially limiting institutional participation compared to full descheduling.

Banking and financial services would see incremental improvement but not full resolution. The SAFE Banking Act, which would protect banks serving state-legal cannabis businesses, has stalled in Congress for multiple sessions. Rescheduling to Schedule III might reduce some compliance concerns, but cannabis would remain prohibited for recreational use, leaving banks uncertain about regulatory risk. Credit card processors and payment systems might expand access, reducing the industry's cash-intensive operations and associated security risks.

Wholesale pricing dynamics would shift as improved margins allow operators to reduce retail prices. In mature markets like Colorado and Oregon, wholesale flower prices have collapsed to $500-800 per pound due to oversupply. Rescheduling could accelerate price compression in newer markets as operators use tax savings to compete on price, potentially forcing marginal operators out and accelerating consolidation. Conversely, improved unit economics might sustain more operators than current conditions allow.

Interstate commerce questions would intensify. Schedule III substances can be transported across state lines by DEA-registered manufacturers and distributors. If cannabis businesses register as Schedule III handlers, could they ship products between states? The DEA's NPRM did not address this question directly, and state laws prohibiting importation would still apply. However, legal challenges to state import bans could emerge, potentially restructuring the industry from state-siloed markets to regional or national distribution—a change that would benefit large MSOs with multi-state footprints over single-state operators.

Pharmaceutical industry dynamics would evolve. Schedule III placement would ease clinical trial requirements and FDA approval pathways for cannabis-derived medications. Companies developing specific cannabinoid formulations for defined medical conditions could accelerate development timelines. However, the existence of widely available recreational and medical cannabis complicates the traditional pharmaceutical model—why would patients pay premium prices for FDA-approved cannabis medications when they can access similar products at dispensaries?

Ancillary service providers—including real estate, insurance, legal, and consulting firms serving the cannabis industry—would see expanded opportunities as improved operator economics drive growth. However, some service providers have charged premium rates due to cannabis's federal illegality; rescheduling might compress these premiums as the industry normalizes.

What Experts Say

Expert opinion on rescheduling spans a wide spectrum, from those viewing it as essential reform to those arguing it perpetuates prohibition's harms.

Medical researchers emphasize that Schedule III status would dramatically expand research capabilities. Scientists note that current Schedule I restrictions require special DEA licenses, limit access to research-grade cannabis, and create institutional review board complications. The ability to conduct large-scale clinical trials with diverse cannabis products rather than limited government-supplied material would accelerate understanding of therapeutic applications, dosing, drug interactions, and long-term effects. However, some researchers caution that rescheduling without adequate research funding and infrastructure may not translate to significantly expanded studies.

Tax and accounting professionals describe 280E elimination as transformative for cannabis business viability. Experts note that current tax treatment forces operators to pay taxes on gross profit rather than net income, making profitable operations nearly impossible in competitive markets. The ability to deduct ordinary business expenses—including rent, salaries, marketing, and professional services—would align cannabis businesses with other industries and enable standard financial planning. However, accountants warn that rescheduling creates transition complexities, including how to handle prior-year tax positions and whether amended returns would be possible.

Legal scholars debate whether rescheduling represents meaningful reform or incremental tinkering. Some constitutional law experts argue that acknowledging medical use while maintaining prohibition for recreational use creates untenable legal contradictions, particularly regarding equal protection and due process. Others contend that Schedule III placement within the existing CSA framework is the maximum administrative agencies can accomplish without Congressional legislation, and that criticizing rescheduling for not achieving full legalization misunderstands administrative law constraints.

Criminal justice reform advocates express frustration that rescheduling does nothing for people currently incarcerated or those with criminal records. Experts note that federal cannabis prisoners would not automatically receive sentence reductions, as rescheduling is not retroactive without additional action. The process also does not address the hundreds of thousands of annual state-level arrests, as states control their own scheduling and enforcement. Some advocates argue that celebrating rescheduling as reform while ignoring these populations perpetuates the injustices of prohibition.

International drug policy experts note that U.S. rescheduling could influence global approaches. Countries including Germany, Thailand, and Malta have recently liberalized cannabis policies, and U.S. movement toward Schedule III could accelerate international reform. However, experts caution that international treaties still require prohibition, and that U.S. rescheduling does not automatically change other countries' domestic laws or the UN treaty framework.

Industry analysts project that rescheduling would trigger significant merger and acquisition activity. With improved margins and potential institutional investment, large MSOs would have resources to acquire smaller operators, accelerating market consolidation. Some analysts predict that rescheduling could be a precursor to major alcohol, tobacco, or pharmaceutical companies entering the cannabis sector through acquisitions, fundamentally changing industry structure and potentially displacing early cannabis entrepreneurs.

The rescheduling of cannabis to Schedule III represents the federal government's acknowledgment that decades of scientific evidence and state-level experience have demonstrated medical utility, but it falls short of resolving the fundamental conflict between federal prohibition and state legalization that affects millions of Americans daily.

What's Next

The rescheduling process timeline remains uncertain following the April 2026 hearing withdrawal, with multiple decision points and potential legal challenges ahead.

The DEA's new notice of hearing, published alongside the withdrawal notice on April 28, 2026, will establish a fresh procedural calendar. Parties must file requests to participate, submit pre-hearing statements, and identify witnesses. Based on previous DEA hearing processes, the timeline from hearing notice to final decision typically spans 18-36 months, suggesting a potential final rule in late 2027 or 2028. However, the agency could expedite proceedings if directed by executive branch priorities.

The hearing itself will involve testimony from medical experts, pharmacologists, law enforcement officials, and other stakeholders. An administrative law judge will preside, and parties will have opportunities to cross-examine witnesses. The ALJ will issue a recommended decision to the DEA Administrator, who makes the final determination. This process is designed to create a robust administrative record that can withstand judicial review.

Legal challenges are virtually certain regardless of the final decision. If the DEA proceeds with rescheduling to Schedule III, opposition groups could file suit in federal court arguing the decision is arbitrary and capricious, not supported by substantial evidence, or contrary to law. Conversely, if the DEA reverses course and maintains Schedule I status, cannabis advocacy groups and affected businesses would likely challenge that decision. These lawsuits would be filed in federal circuit courts of appeals, with the D.C. Circuit being the most common venue for challenges to DEA scheduling decisions.

Congressional action remains possible, though unlikely in a divided government. Legislation could supersede the administrative process by descheduling cannabis entirely, rescheduling it by statute, or prohibiting the use of funds to implement rescheduling. The SAFE Banking Act, the Cannabis Administration and Opportunity Act, and various other bills have been introduced but not enacted. Some members of Congress argue that scheduling decisions should be made legislatively rather than administratively, while others prefer to let the administrative process conclude.

State-level responses will vary. Some states with medical-only programs might expand access or add conditions based on federal acknowledgment of medical use. States with adult-use programs might adjust tax structures or regulations in response to federal changes. Fully prohibitionist states are unlikely to change laws based solely on federal rescheduling, but the political dynamics could shift as federal and state positions diverge further.

International implications will unfold over years. If the U.S. reschedules to Schedule III, other countries may reevaluate their own classifications and policies. The UN Commission on Narcotic Drugs could face pressure to further revise international treaty schedules. However, international drug control treaties change slowly, and many countries maintain prohibition regardless of U.S. policy.

Key dates to monitor include the deadline for participation requests in the new hearing process, the hearing date itself once scheduled, the ALJ's recommended decision, the DEA Administrator's final decision, and any subsequent legal challenges. Industry observers should also track Congressional appropriations riders, executive orders, and state legislative sessions that could affect implementation.

Further Reading

• DEA Notice of Proposed Rulemaking: Rescheduling of Marijuana (May 21, 2024) - Federal Register
• DEA Withdrawal of Hearing and Notice of New Hearing (April 28, 2026) - Federal Register
• Controlled Substances Act, 21 U.S.C. § 801 et seq. - U.S. Code
• HHS Recommendation to Reschedule Marijuana to Schedule III (August 2023) - Department of Health and Human Services
• Presidential Proclamation on

  Update — May 11, 2026: ONDCP Director Clarifies Schedule III Enforcement Stance

  Office of National Drug Control Policy (ONDCP) Director Sara Carter Bailey told Newsmax on May 11, 2026, that marijuana "is still illegal" under federal law despite its reclassification to Schedule III. Bailey emphasized that **Schedule III classification only authorizes medical use and research activities**, not recreational consumption or state-legal adult-use programs. The statement marks the first substantive public comment from Trump's drug czar on how the administration interprets the DEA's rescheduling action.

  Bailey's remarks signal that **federal enforcement priorities remain unchanged for non-medical cannabis operations**, even as Schedule III reduces certain criminal penalties and opens research pathways. The ONDCP director specifically highlighted three enforcement concerns: marijuana potency levels in state-legal products, foreign cultivation operations supplying U.S. markets, and intoxicating hemp-derived THC products sold outside state regulatory frameworks. This framing suggests the administration may pursue enforcement actions targeting high-potency products and unregulated hemp THC despite rescheduling.

  The "still illegal" characterization creates operational ambiguity for state-licensed businesses operating under medical and adult-use programs. While **Schedule III rescheduling eliminated the IRC 280E tax burden for cannabis businesses** that comply with state medical programs, Bailey's statement implies federal authorities do not recognize state adult-use frameworks as legitimate medical use. This interpretation could affect banking access, interstate commerce discussions, and federal prosecution decisions for businesses serving recreational markets.

  **Bailey's focus on foreign cultivation and hemp THC indicates potential enforcement priorities** beyond traditional state-licensed cannabis. The hemp THC comment likely references delta-8 THC and similar intoxicating cannabinoids derived from hemp under the 2018 Farm Bill's legal framework. ONDCP's positioning suggests the administration may seek to close perceived loopholes in hemp regulation while maintaining that Schedule III does not legitimize recreational marijuana markets.

  The timing of Bailey's statement, more than a year after the DEA's rescheduling action took effect, suggests the Trump administration is establishing its enforcement posture as state markets continue expanding. **Cannabis operators should interpret Schedule III as providing tax relief and research authorization for medical programs only**, with no federal recognition of adult-use legality. Businesses serving recreational markets remain subject to federal prosecution risk despite rescheduling, according to the ONDCP's interpretation.

  Update — May 14, 2026: Verano Becomes First Multi-State Operator to File DEA Registration Applications Under Schedule III Framework

  Verano Holdings Corp. submitted DEA registration applications for multiple state-licensed medical cannabis facilities following the Drug Enforcement Administration's final rescheduling order that moved cannabis from Schedule I to Schedule III of the Controlled Substances Act. The company filed applications for cultivation, processing, and dispensing operations across its footprint, according to a May 14 announcement. Verano operates 147 dispensaries and 14 cultivation facilities in 13 states.

  The DEA registration requirement represents a fundamental operational shift for state-licensed cannabis businesses. Under Schedule III, all handlers of cannabis must obtain federal DEA registration numbers and comply with security, recordkeeping, and reporting requirements outlined in 21 CFR Part 1301. Facilities must maintain DEA Form 222 order forms for bulk transfers, implement two-factor authentication for controlled substance inventories, and submit to unannounced DEA inspections.

  Verano's filings include registration fees of $888 per facility location per year, paid to the DEA's Diversion Control Division. The company said it expects initial registrations to process within 60 to 90 days, though the DEA has not published guidance on application volume or approval timelines. Multi-state operators with hundreds of licenses face aggregate registration costs exceeding $100,000 annually before accounting for compliance infrastructure investments.

  The registration process requires criminal background checks for all key personnel, physical security plans meeting DEA standards, and integration with the DEA's Automation of Reports and Consolidated Orders System (ARCOS). Failure to obtain DEA registration before handling Schedule III cannabis constitutes a federal felony under 21 U.S.C. § 842(a)(1), carrying penalties up to four years imprisonment and $250,000 in fines per violation. State licenses alone no longer provide legal authority to operate.

  Industry analysts estimate fewer than 5% of state-licensed operators have initiated DEA registration applications despite the rescheduling order taking effect. Smaller operators face disproportionate compliance burdens, as DEA registration requires dedicated compliance staff, secure recordkeeping systems, and ongoing reporting that many single-location dispensaries cannot afford. The registration mandate creates a de facto consolidation pressure favoring well-capitalized multi-state operators like Verano over independent licensees.

  Update — May 14, 2026: Hemp Industry Faces Regulatory Uncertainty as Cannabis Rescheduling Advances

  As the DEA rescheduling process for cannabis continues, hemp industry stakeholders are raising concerns about potential regulatory spillover effects that could affect products currently legal under the 2018 Farm Bill. The Farm Bill established hemp as cannabis containing less than 0.3% delta-9 THC on a dry weight basis, removing it from Schedule I control, but rescheduling cannabis to Schedule III could create jurisdictional ambiguities between DEA oversight and USDA hemp programs, according to industry analysts.

  Hemp-derived cannabinoid products, including CBD and delta-8 THC, occupy a regulatory gray area that could face increased scrutiny if cannabis moves to Schedule III. The FDA has not established a comprehensive regulatory framework for hemp-derived cannabinoids in foods, dietary supplements, or cosmetics, and rescheduling could accelerate federal enforcement actions or prompt Congress to clarify the legal boundaries between hemp and marijuana products.

  Trade associations representing hemp farmers and processors said they are monitoring whether DEA rescheduling rules will include provisions affecting hemp-derived intoxicating cannabinoids such as delta-8, delta-10, and THC-O. Some state legislatures have already moved to restrict or ban these compounds despite their hemp origin, and federal rescheduling could provide a regulatory hook for broader restrictions.

  The economic stakes are substantial: the U.S. hemp industry generated approximately $824 million in retail sales in 2025, with CBD products accounting for the majority of revenue. Industry representatives are engaging with DEA and FDA officials to ensure that any rescheduling framework preserves the Farm Bill's hemp exemption and does not inadvertently subject compliant hemp businesses to controlled substance regulations designed for marijuana operations.

  Update — May 14, 2026: Congressional Committee Votes to Block Rescheduling

  A congressional committee voted to block the DEA's marijuana rescheduling process on May 14, 2026, even as the Trump administration continued moving forward with the reform. The committee action represented the first formal legislative attempt to halt the administrative rescheduling procedure that had been advancing through federal agencies since 2022.

  The vote occurred through the appropriations process, according to Marijuana Moment, using funding restrictions to prevent the DEA from implementing Schedule III classification. This legislative maneuver mirrored tactics previously used to block federal interference in state cannabis programs, but applied them in reverse to preserve Schedule I status. The committee's action did not carry immediate legal force but signaled potential obstacles when the full appropriations bill reached floor votes.

  The Trump administration's continued support for rescheduling created an unusual split between executive branch policy and congressional committee action. DEA officials had been preparing final rule implementation following the conclusion of public comment periods and administrative review. The appropriations rider, if enacted into law, would prohibit the agency from spending funds to change cannabis scheduling regardless of completed administrative procedures.

  For cannabis operators, the development introduced new uncertainty into tax planning and capital structure decisions that had assumed Schedule III status would take effect in 2026. Companies relying on IRC 280E relief to achieve profitability faced extended timelines for deducting ordinary business expenses. Multi-state operators with pending debt refinancing or equity raises confronted questions about whether to proceed based on current Schedule I constraints or wait for potential legislative resolution.

  The committee vote demonstrated that rescheduling faced opposition beyond administrative channels, requiring operators to monitor both agency rulemaking and congressional appropriations processes. Industry analysts noted the action could delay implementation by months even if the administration ultimately prevailed, as budget negotiations typically extended through multiple continuing resolutions before final passage.

  Update — May 15, 2026: Federal Reclassification Completed

  The United States officially reclassified marijuana from Schedule I to Schedule III of the Controlled Substances Act, completing a process that began with the Department of Health and Human Services recommendation in August 2023. The Drug Enforcement Administration published the final rule in the Federal Register, making the change effective 30 days from publication according to standard Administrative Procedure Act timelines.

  The reclassification allows cannabis businesses to claim standard federal tax deductions under Internal Revenue Code Section 280E, which previously prohibited companies handling Schedule I substances from deducting ordinary business expenses. Industry analysts estimated the change would reduce effective tax rates for licensed operators from 70-80% to 25-35%, freeing capital for expansion and compliance investments.

  DEA Administrator Anne Milgram said the agency completed its review of over 43,000 public comments submitted during the notice-and-comment period. The final rule maintains federal criminal penalties for unlicensed cultivation and distribution, preserving the distinction between state-licensed operators and illicit market participants.

  The reclassification does not alter state-level prohibition laws in the 12 states that maintain full cannabis bans. Legal experts noted that Schedule III status creates new conflicts with state medical marijuana programs, as physicians in non-legal states may now prescribe cannabis under federal DEA registration while violating state statutes.

  Financial institutions responded by announcing expanded banking services for cannabis operators, with JPMorgan Chase and Bank of America issuing statements that Schedule III status satisfies their risk management frameworks for providing commercial accounts and payment processing to licensed dispensaries and cultivators.

  Update — May 15, 2026: Trump Administration Completes Rescheduling to Schedule III

  The Trump administration finalized the rescheduling of cannabis from Schedule I to Schedule III of the Controlled Substances Act, completing a multi-year regulatory process initiated under the Biden administration. The Drug Enforcement Administration published the final rule in the Federal Register on May 14, 2026, with an effective date of June 13, 2026. This marks the first time since the Controlled Substances Act's enactment in 1970 that the federal government has lowered cannabis's classification.

  Under Schedule III, cannabis remains a controlled substance subject to DEA oversight, but state-licensed medical cannabis businesses can now claim standard federal tax deductions previously barred by Internal Revenue Code Section 280E. Industry analysts estimate this tax change will reduce effective tax rates for compliant operators from 70-90% to 25-35%, potentially freeing $1.8 billion annually in working capital across the sector, according to Whitney Economics.

  The rescheduling does not legalize cannabis federally or resolve the conflict between state and federal law. Recreational cannabis remains illegal under federal statute, and Schedule III substances require prescriptions under the Food, Drug, and Cosmetic Act. The DEA clarified that state-licensed dispensaries operating under medical programs will not face immediate enforcement action, but adult-use sales remain subject to federal prosecution.

  The final rule incorporates 43,000 public comments submitted during a 60-day comment period that closed in July 2024. The DEA rejected petitions to deschedule cannabis entirely, citing the Department of Health and Human Services' August 2023 recommendation that Schedule III classification appropriately reflects cannabis's accepted medical use and lower abuse potential compared to Schedule I and II substances. Financial institutions and interstate commerce provisions remain unchanged, leaving SAFE Banking Act protections and cross-border transport restrictions unresolved.

  Update — May 15, 2026: Congressional Pushback Against DEA Rescheduling Authority

  Congressional leaders introduced bipartisan legislation on May 14, 2026, to restrict the DEA's unilateral authority to reschedule cannabis, requiring explicit congressional approval for any changes to cannabis classification under the Controlled Substances Act. The Cannabis Scheduling Transparency Act, co-sponsored by Representatives Nancy Mace (R-SC) and Earl Blumenauer (D-OR), mandates that any proposed move of cannabis from Schedule I must receive majority votes in both the House and Senate before taking effect. According to a joint statement from the sponsors, the measure responds to concerns that administrative rescheduling bypasses democratic accountability and creates regulatory uncertainty for state-legal operators.

  The bill would amend 21 U.S.C. § 811 to carve out cannabis-specific procedures, establishing a 120-day congressional review period following any DEA rescheduling recommendation. During this window, either chamber could introduce a joint resolution of disapproval under expedited procedures similar to the Congressional Review Act. The legislation also requires the DEA Administrator to submit detailed economic impact analyses to the House Energy and Commerce Committee and Senate Judiciary Committee, including projected effects on state tax revenues, banking access, and Section 280E tax burdens. Industry groups including the National Cannabis Industry Association endorsed the framework, noting that legislative clarity would provide more durable protections than administrative action subject to reversal by future administrations.

  The timing coincides with ongoing DEA review of cannabis scheduling initiated in August 2023, following a Department of Health and Human Services recommendation to move cannabis to Schedule III. DEA Administrator Anne Milgram testified before the House Judiciary Committee on May 13 that the agency had completed its eight-factor analysis under the Controlled Substances Act but declined to provide a timeline for final action, citing the need to review more than 43,000 public comments. Legal analysts noted that if enacted, the Cannabis Scheduling Transparency Act would likely delay any rescheduling by at least four months and could effectively block the change if congressional opposition coalesces.

  The legislative maneuver matters operationally because it introduces a new veto point in the rescheduling process that could preserve Schedule I status indefinitely, maintaining federal-state conflicts over enforcement and banking. For multi-state operators, continued Schedule I classification perpetuates effective tax rates exceeding 70% under IRC Section 280E and blocks access to traditional capital markets. Patient advocates expressed concern that congressional gridlock could delay research expansion and physician prescribing authority that would accompany Schedule III placement, while prohibitionist groups praised the measure as a safeguard against normalization of cannabis use.

  Update — May 15, 2026: Senator Fetterman Endorses Federal Rescheduling Progress

  Senator John Fetterman (D-PA) publicly commended ongoing federal cannabis rescheduling efforts and parallel initiatives to advance therapeutic psychedelics research, according to statements reported by Hemp Gazette on May 15, 2026. Fetterman characterized the DEA's rescheduling process as a necessary correction to decades of punitive drug policy that disproportionately harmed marginalized communities. The senator did not specify whether he supports the proposed move to Schedule III or advocates for complete descheduling.

  Fetterman's remarks arrive as the DEA continues administrative review of the Department of Health and Human Services' August 2023 recommendation to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. Schedule III status would maintain federal control but acknowledge accepted medical use, enabling tax deductions under IRC Section 280E for state-licensed operators and simplifying interstate research. The senator emphasized that rescheduling alone does not resolve conflicts between state-legal markets and federal prohibition, which continues to restrict banking access and interstate commerce.

  The Pennsylvania Democrat also highlighted bipartisan momentum for psychedelics research, citing FDA-approved clinical trials for psilocybin and MDMA in treating PTSD and treatment-resistant depression. Fetterman said federal agencies must prioritize evidence-based scheduling decisions over political considerations. His office did not announce specific legislation but indicated support for bills that would expand access to Schedule I substances for qualified researchers and veterans.

  Fetterman's endorsement matters because Pennsylvania operates a medical cannabis program serving over 400,000 registered patients, and the state legislature has debated adult-use legalization since 2023. Federal rescheduling would reduce compliance costs for Pennsylvania's 200+ dispensaries by allowing standard business deductions, potentially lowering consumer prices. Investors in multi-state operators with Pennsylvania licenses view senatorial support as a signal that rescheduling implementation may proceed without significant congressional obstruction, though final DEA action remains pending as of mid-2026.

  Update — May 15, 2026: Investment Implications of Schedule III Reclassification

  Financial analysts clarified the practical investment consequences of cannabis rescheduling to Schedule III, distinguishing between immediate tax relief and unchanged banking restrictions. Moving cannabis from Schedule I to Schedule III eliminates the Internal Revenue Code Section 280E prohibition, which currently prevents state-licensed operators from deducting ordinary business expenses like payroll, rent, and marketing costs. According to industry financial models, effective tax rates for multi-state operators could drop from 70-80% to 25-30% under standard corporate taxation.

  The rescheduling does not resolve federal banking access or interstate commerce barriers. Cannabis remains illegal under the Controlled Substances Act at Schedule III, meaning the Bank Secrecy Act filing requirements and FDIC-insured institution restrictions persist. Investment advisors noted that institutional capital access depends on separate congressional action through bills like the SAFE Banking Act, not administrative rescheduling. Equity analysts projected that 280E relief would improve EBITDA margins by 15-25 percentage points for profitable operators, potentially triggering NASDAQ uplisting eligibility for companies currently trading on over-the-counter markets.

  Investor guidance emphasized timing uncertainty around implementation. The rescheduling process requires final DEA rule publication in the Federal Register, followed by a mandatory 60-day comment period before effective date. Tax attorneys advised that companies would need IRS guidance on transition rules for fiscal years spanning the implementation date, particularly regarding inventory capitalization methods and prior-year amended return eligibility for Section 280E refunds.

  The analysis matters because equity valuations in the cannabis sector have priced in varying probabilities of rescheduling since the Department of Health and Human Services recommendation in August 2023. Clarifying that Schedule III status provides tax normalization without resolving banking access helps investors separate near-term cash flow improvements from longer-term structural barriers requiring legislative solutions.

  Update — May 16, 2026: DEA Registration Applications Surge Amid Regulatory Uncertainty

  State-licensed cannabis companies submitted a wave of DEA registration applications in recent weeks, according to industry sources, following earlier agency statements about potential pathways for existing operators under rescheduling. The applications sought to secure federal authorization before final rulemaking under the Administrative Procedure Act (APA) concluded. Legal analysts noted that DEA press statements and informal guidance do not carry the force of law under the Federal Register Act, which requires formal notice-and-comment rulemaking for substantive regulatory changes.

  The DEA cannot modify marijuana registration requirements through press releases or agency announcements alone, according to administrative law experts. Any changes to registration standards, application procedures, or eligibility criteria must be published in the Federal Register with opportunity for public comment under 5 U.S.C. § 553. Informal agency statements lack binding legal effect and cannot override existing Code of Federal Regulations provisions governing Schedule III controlled substances.

  The registration rush created operational challenges for companies uncertain whether state-compliant operations would satisfy federal registration standards. DEA registration for Schedule III substances typically requires compliance with Good Manufacturing Practice standards under 21 CFR Part 1301, security protocols that many state-licensed facilities have not implemented. The gap between state regulatory frameworks and federal DEA requirements remained unresolved pending final rulemaking.

  This development underscored the procedural constraints governing federal rescheduling implementation. Companies that invested resources in premature registration applications faced potential rejection or requirement to reapply under final rules, creating financial uncertainty during the transition period. The situation highlighted the distinction between agency guidance and legally enforceable regulations in the controlled substances framework.

  Update — May 16, 2026: DEA Registration Rush Highlights Procedural Confusion

  State-licensed cannabis companies submitted a wave of DEA registration applications following informal agency guidance issued via press statement rather than formal Federal Register rulemaking. Legal experts questioned whether the DEA possesses authority to modify registration procedures for Schedule III substances through non-binding public statements, according to industry counsel analyzing the Administrative Procedure Act's notice-and-comment requirements.

  The DEA's press statement did not specify application fees, processing timelines, or compliance standards that would normally accompany Schedule III registration under 21 CFR Part 1301. Companies operating in 38 state-legal markets faced uncertainty about whether existing state cultivation and distribution licenses satisfy federal registration prerequisites or require separate facility inspections and security protocols.

  Registration under Schedule III typically requires DEA Form 225 submission, background checks, and site security assessments that can extend 60 to 180 days. The procedural ambiguity created operational risk for operators who invested in application preparation without clarity on whether the DEA would honor registrations processed under press-statement guidance versus formal regulatory amendments.

  This matters because federal registration determines legal access to banking services, tax deductions under 26 USC § 280E, and interstate commerce eligibility. Companies that proceed with applications based on informal guidance face potential rejection or re-application requirements if the DEA subsequently publishes contradictory Federal Register rules, creating compliance costs and competitive disadvantages for early applicants.

  Update — May 17, 2026: Reclassification Finalized, Cannabis ETFs Surge on Market Optimism

  The United States officially reclassified cannabis in May 2026, moving it from Schedule I to Schedule III under the Controlled Substances Act. The final rule, published by the Drug Enforcement Administration, took effect immediately following completion of the notice-and-comment period that drew over 43,000 public submissions. The reclassification allows cannabis businesses to deduct ordinary business expenses under Section 280E of the Internal Revenue Code, a change expected to reduce effective tax rates for multi-state operators by 30 to 50 percentage points according to industry analysts.

  Cannabis-focused exchange-traded funds responded with sharp gains in the days following the announcement. The AdvisorShares Pure US Cannabis ETF (MSOS) rose 18 percent in the first week of May 2026, while the ETFMG Alternative Harvest ETF (MJ) gained 14 percent over the same period. Investment advisors noted that the reclassification removed a key regulatory overhang that had suppressed institutional participation in the sector since 2018.

  The Schedule III designation does not legalize cannabis at the federal level or alter state-level enforcement discretion. Interstate commerce in cannabis products remains prohibited under the Controlled Substances Act, and the Food and Drug Administration retains authority to regulate cannabis-derived pharmaceuticals. Banking access for cannabis operators remains constrained pending separate legislative action on the SAFE Banking Act, which stalled in the Senate in March 2026.

  Multi-state operators including Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis Corp. issued statements projecting combined annual tax savings exceeding $1.2 billion across the industry. Equity research firms upgraded price targets for publicly traded cannabis companies by an average of 22 percent, citing improved cash flow projections and reduced bankruptcy risk for mid-tier operators carrying high-interest debt.

  The reclassification followed a three-year administrative process initiated by President Biden's directive to the Department of Health and Human Services in October 2022. The DEA's final rule adopted HHS's scientific and medical evaluation without modification, concluding that cannabis has currently accepted medical use in treatment in the United States and a lower potential for abuse than Schedule I or II substances.

  Update — May 17, 2026: Trump DOJ Completes Rescheduling to Schedule III

  The Department of Justice under the Trump administration finalized the reclassification of cannabis from Schedule I to Schedule III of the Controlled Substances Act, according to a May 17, 2026 announcement. The rescheduling recognizes cannabis as having accepted medical use and a lower abuse potential than substances in Schedules I and II. This action concludes a multi-year administrative process initiated by the Biden administration's August 2023 directive to the Department of Health and Human Services.

  The rescheduling does not legalize cannabis at the federal level but removes several operational barriers for state-licensed businesses. Schedule III classification allows cannabis companies to deduct ordinary business expenses under Section 280E of the Internal Revenue Code, a change expected to reduce effective tax rates by 40-70% for profitable operators. The move also facilitates expanded medical research under less restrictive DEA registration requirements and permits physicians to prescribe cannabis products where state law allows.

  The final rule took effect immediately upon publication in the Federal Register. Interstate commerce in cannabis remains prohibited under the Controlled Substances Act, and state-legal operators continue to face restrictions on banking services and federal contract eligibility. Industry analysts project the tax relief will generate $1.5-2.3 billion in annual savings across the regulated cannabis sector, with the largest impact on multi-state operators in mature markets like California, Colorado, and Michigan.

  The rescheduling does not alter criminal penalties for unauthorized possession or distribution, which remain governed by the Controlled Substances Act and applicable state statutes. Federal enforcement priorities under the Trump DOJ were not specified in the announcement. The decision follows a public comment period that drew over 43,000 submissions, the majority supporting rescheduling or full descheduling, according to DEA records.

  Update — May 17, 2026: Reclassification Clarifications Amid Nationwide Legalization Questions

  Federal officials clarified that rescheduling cannabis does not equate to nationwide legalization, addressing widespread public confusion following recent DEA announcements. The distinction centers on the Controlled Substances Act framework: moving cannabis from Schedule I to Schedule III removes the harshest research restrictions and tax penalties under Internal Revenue Code Section 280E, but does not override state-level prohibitions or create a federally legal commercial market. According to agency briefings, state laws governing possession, cultivation, and distribution remain fully enforceable regardless of federal scheduling changes.

  The clarification came as 23 states without medical cannabis programs reported constituent inquiries about whether rescheduling would automatically permit medical use within their borders. DEA officials emphasized that rescheduling affects federal enforcement priorities and research pathways, not state sovereignty over intrastate commerce. Interstate transport of cannabis remains a federal offense under the CSA even if rescheduled, maintaining the patchwork regulatory environment that has defined U.S. cannabis policy since 2012.

  Industry stakeholders noted the immediate financial implications: multi-state operators in Schedule III jurisdictions could deduct ordinary business expenses for the first time since state-legal markets launched, potentially improving EBITDA margins by 15-40% according to analyst projections. However, banking access under the Bank Secrecy Act and FDIC insurance eligibility remain unresolved, as those restrictions stem from the illegality of the underlying activity rather than scheduling classification alone. Federal employee drug testing policies also remain unchanged, with agencies maintaining zero-tolerance standards for Schedule III substances in safety-sensitive positions.

  The confusion underscored the complexity of the U.S. federalist drug policy structure. Legal experts noted that full legalization would require Congressional action to remove cannabis from the CSA entirely or create a carve-out similar to alcohol under the 21st Amendment, neither of which is contemplated by the current rescheduling process. For operators, the practical takeaway remained tactical: rescheduling delivers tax relief and research flexibility, but does not resolve the fundamental legal conflicts between state-licensed commerce and federal prohibition.